Login to Your Account



Other News To Note


Monday, December 20, 2010
DiaGenic ASA, of Oslo, Norway, and Pfizer Inc., of New York, have signed an agreement for an explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription